Akhil Abraham Saji, MD
Akhil Abraham Saji, MD, is a urologist specializing in minimally invasive surgery and urologic oncology with an interest in technology-driven innovation within health care.
Articles by Akhil Abraham Saji, MD
NARUS served as a platform for surgeons to share insights into the advancements and future directions of robotic surgery.
Highlighting some of the primary advancements identified within urologic oncology during 2023 and what to anticipate in 2024.
A combination of current guidelines and RCTs give surgeons clarity on the benefit of extended PLND in bladder cancer.
A review of some of the latest techniques and applications of the SP platform for kidney and upper urinary tract surgery.
The meeting covers a range of topics, including prostate cancer, kidney cancer, and bladder cancer, as well as penile cancer.
This is the first trial that has shown an OS benefit improvement over chemo in the 1L mUC setting, a landmark achievement.
Surgery in advanced RCC has come into question and requires further clarification on when and how it should be utilized.
This review highlights some of the most exciting abstracts and presentations in GU oncology at the ESMO Congress 2023.
Patients considering PC screening should talk to their PCP or urologist about the benefits and risks of identifying PC early.
The da Vinci Single Port platform allows robot-assisted surgical procedures with the same precision as multiport techniques.
Increasing competition in robot-assisted surgical platform production will increase accessibility for patients everywhere.
PSMA PET imaging is a leap forward in the fight to cure prostate cancer, especially as theranostic capabilities expand.
What role can artificial intelligence play in the diagnosis and management of prostate cancer utilizing MRI?
One might assume that the AUA meeting is geared toward practicing urologists, but it is also crucial for urologic trainees.
The postsurgical treatment of functional outcomes such as UI and ED after SRP remains a challenge for all urologists.
FDA approval of Adstiladrin for use in BCG-unresponsive NMIBC expands the armamentarium for treatment of high-risk NMIBC.
Drs. David Ambinder and Akhil Saji highlight the importance of attending the AUA meeting as urology residents.
NMIBC-associated costs vary widely across types of treatments utilized, health systems, and regions of the country.
The minimally invasive options available to patients diagnosed with muscle-invasive disease of urothelial origin are limited.
This review highlights the existing research regarding the financial toxicity of advanced prostate cancer.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.